Akebia Q3 Auryxia revenue up 14.9% to $42.2M; files FDA dispute for vadadustat

Akebia Therapeutics, Inc.

2022-Q3 EPS reported -$0.47 revenue$237,422,000

Net product revenue $42.2M (+14.9% YoY); total revenue $49.0M vs $48.8M YoY.
Net loss $51.9M vs $59.5M YoY; cash $144.8M, sufficient for at least 12 months.
Filed Formal Dispute Resolution Request with FDA over vadadustat CRL; response expected by end-2022.
Retired $33M of Pharmakon debt; 2022 Auryxia revenue guidance reaffirmed at $170-175M.
Assumed EU marketing application for vadadustat; EMA decision expected Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Akebia Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $49.0 million.

Period: the third quarter ended September 30, 2022
Revenue: $49.0 million
Result: reported results

Exact text from the filing

net price per pill puts us in a position to affirm our 2022 net product revenue guidance for Auryxia of $170 - $175 million.” Financial Results • Revenues: Total revenue was $49.0 million in the third quarter of 2022 compared to $48.8 million for the third quarter of 2021. • Net product revenue was $42.2 million in the third quarter of 2022 compared to $36.8

View on SEC.gov

Browse all earnings releases →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-276930

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.